Zealand Pharma Soars on Positive Weight-Loss Drug Trial Results
TL;DR Summary
Zealand Pharma's stock rose 17% after announcing that its experimental weight loss drug petrelintide showed similar efficacy to Ozempic with fewer side effects in a phase 1 trial. Petrelintide, a long-acting amylin analog, could be an alternative for patients who can't tolerate GLP-1 treatments.
- Zealand Pharma stock surges 23% on results for its Ozempic alternative Quartz
- Weight loss drug contender Zealand Pharma jumps 18% on trial results CNBC
- What To Know About Zealand Pharma's Petrelintide—An Ozempic Competitor Forbes
- Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s MarketWatch
- Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 2 min read
Condensed
87%
349 → 44 words
Want the full story? Read the original article
Read on Quartz